Novel therapeutic agents for osteosarcoma

Kathleen O'Day, Richard Gorlick

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations


Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.

Original languageEnglish (US)
Pages (from-to)511-523
Number of pages13
JournalExpert Review of Anticancer Therapy
Issue number4
StatePublished - 2009


  • Chemotherapy
  • Novel agent
  • Osteosarcoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Novel therapeutic agents for osteosarcoma'. Together they form a unique fingerprint.

Cite this